

NH2
VL
K-coil
(or E-coil)
Polypeptide Chain 1
COOH
C
VH
Linker 2
Linker 1
Linker 2
Polypeptide Chain 2
COOH
C
VH
E-coil
(or K-coil)
VL
NH2
Assembled Diabody
NH2
VL
VH
COOH
C
COOH
C
VH
VL
NH2

Figure 1



Polypeptide Chain 1
COOH
CH3
CH2
Peptide 1
K-coil
(or E-coil)
Linker S
Linker 2
NH2
VL
VH
Linker 1
Polypeptide Chain 2
Linker 2
COOH
E-coil
(or K-coil)
VH
VL
NH2
Polypeptide Chain 3
CH3
COOH
CH2
Peptide 1
NH2
Assembled Fc Diabody (Version 1)
COOH
CH3
CH3
COOH
CH2
CH2
NH2
VL
VH
VH
VL
NH2

Figure 2A



Peptide 1
NH2
C
C
CH2
CH3
Linker 4
VL
K-coil
(or E-coil)
Polypeptide Chain 1
COOH
C
VH
Linker 2
Linker 1
Linker 2
Polypeptide Chain 2
COOH
C
VH
E-coil
(or K-coil)
VL
NH2
Peptide 1
Polypeptide Chain 3
NH2
C
C
CH2
CH3
COOH
Assembled Fc Diabody (Version 2)
Peptide 1
NH2
C
C
NH2
C
C
CH2
CH2
CH3
CH3
COOH
VL
COOH
C
VH
COOH
C
VH
VL
NH2

Figure 2B



shCD3 capture/gpA33 detection
gpA33 x CD3 DART-1
Control DART
FLU
500000
400000
300000
200000
100000
0
0.001
0.01
0.1
1
10
Conc (μg/ml)

Figure 3




Figure 4A




Figure 4B




Figure 4C




Figure 5A




Figure 5B




Figure 5C




Figure 5D




Figure 5E




Figure 5F




Figure 6A




Figure 6B




Figure 6C




Figure 6D




Figure 7A




Figure 7B




Figure 7C




Figure 7D



Tumor Volume (mm3)
3000
2000
1000
0
0
10
20
30
Study Day
Vehicle
gpA33xCD3 DART-1 (0.02 mg/kg)
gpA33xCD3 DART-1 (0.1 mg/kg)
gpA33xCD3 DART-1 (0.5 mg/kg)

Figure 8

Figure 9A: Day 2 Imaging Data (Vehicle):




Figure 9B: Day 2 Imaging Data (gpA33 x CD3 DART-1 (0.5 mg/kg)):




Figure 9C: Day 12 Imaging Data (Vehicle):





Figure 9D: Day 12 Imaging Data (gpA33 x CD3 DART-1 (0.5 mg/kg)):





800
700
600
500
400
300
200
100
0
Tumor Volume (mm3)
0
10
20
30
40
50
Study Day
Vehicle
Control DART (0.5 mg/kg)
gpA33xCD3 DART-1 (0.5 mg/kg)
gpA33xCD3 DART-1 (0.1 mg/kg)
gpA33xCD3 DART-1 (0.02 mg/kg)

Figure 10



Tumor Volume (mm3)
4000
3500
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
Study Day
Vehicle
gpA33xCD3 DART 2 w/Fc version 1 (3.1 mg/kg/day)
gpA33xCD3 DART 2 w/Fc version 1 (1.5 mg/kg/day)
gpA33xCD3 DART 2 w/Fc version 1 (0.75 mg/kg/day)
gpA33xCD3 DART 2 w/Fc version 1 (0.375 mg/kg/day)
gpA33xCD3 DART 2 w/Fc version 1 (0.5 mg/kg/day)

Figure 11





Tumor Volume (mm3)
80
70
60
50
40
30
20
10
0
Vehicle
(0.2 mg/kg)
(0.04 mg/kg)
(0.008 mg/kg)
(0.0016 mg/kg)
(0.5 mg/kg)
gpA33 x CD3 DART-2 w/Fc version 1

Figure 12




□ gpA33 x CD3 DART-2 (Monkey 1)
○ gpA33 x CD3 DART-2 (Monkey 2)
■ gpA33 x CD3 DART-2 w/Fc Version 1 (Monkey 3)


Figure 13




DART-2 w/Fc Version 1 Binding of Human CD3
Figure 14A



DART-2 w/Fc Version 1 Binding of Cynomolgus CD3
Figures 14B



DART-2 w/Fc Version 1 Binding of Human gpA33
Figures 15A



DART-2 w/Fc Version 1 Binding of Cynomolgus gpA33
Figures 15B